• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people > Leadership > Executive Team
Sergio Sosa Estani

Dr Sergio Sosa-Estani

Continental Lead Americas and Latin America Director, DNDi

  • Sergio Sosa-Estani
  • @ssosaestani

Sergio Sosa-Estani, MD, MPH, PhD, Medical Surgeon, joined DNDi in December 2016. Dr Sosa-Estani is currently the Latin America Director. He joined DNDi’s Executive Team in January 2025 as Continental Lead for the Americas.

Dr Sosa-Estani has led many epidemiological and clinical research projects on tropical and infectious Chagas disease, leishmaniasis, HIV/AIDS, Shiga toxin-producing Escherichia coli (STEC), and hantavirus. He joined DNDi from the National Institute of Parasitology ‘Dr. Mario Fatala Chaben’, Argentinian Ministry of Health, where he served as Institute Director.

Dr Sosa-Estani was DNDi’s Head of Chagas Program from 2017 until 2021. He was also a Researcher of the National Council of Scientific and Technological Research (CONICET) in Argentina. He has occupied several positions leading control programmes and research institutions, also serving as advisor at national and international organizations such PAHO/WHO.

Dr Sosa-Estani is physician graduate in medicine at School of Medicine, University of Córdoba-Argentina; Magister in Public Health, School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro- Brazil; Doctor in Medicine, School of Medicine, University of Buenos Aires-Argentina; and earned a post-doctoral degree at CEBGH/SPHTM Tulane University, New Orleans-USA. His scientific production includes more than 120 original articles; 11 book chapters and 2 theses.

 

 

Featured news & publications

Loading...
  • Como acabar de vez com as doenças negligenciadas?
  • Congenital Chagas disease: A cohort study to assess molecular diagnostic methods at the Chagas disease national reference center of Argentina
  • A standardized clinical database for research in Chagas disease: The NHEPACHA network
  • Paediatric malaria treatment developed in Brazil by not-for-profit organizations distributed to Indigenous children in the Amazon region
  • Identificaron un compuesto que puede actuar contra el dengue y Zika
  • Dengue surge grips Latin America
  • Cuáles son las terapias específicas contra el virus del dengue que investiga la ciencia
  • A corrida ‘urgente’ para encontrar remédios efetivos contra a dengue
  • Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial
  • Facing the escalating burden of dengue: Challenges and perspectives

Featured events

Loading...
  • Fostering Ibero-American scientific collaboration for a sustainable future: Health and climate change
  • 7th ABCF Congress
  • XI Chagas Platform Plenary Meeting
  • XVIII Congreso Colombiano de Parasitología e Medicina Tropical
  • World Hepatitis Summit 2022

Our global footprint

Loading...
Doctors talking with patient in hospital

DNDi DRC

Female healthcare worker taking care of a little girl

DNDi Eastern Africa

DNDi Japan

Female patient discussing with doctor

DNDi Latin America

Female doctor with a patient in a hospital

DNDi North America

Community worker talking with people in a rural village

DNDi South Asia

Malaysian doctor talking with a man in a hospital

DNDi South-East Asia

Two people speaking in an office

DNDi Switzerland

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License